133 related articles for article (PubMed ID: 24130322)
1. Ranolazine's sweet side--improvement of glycaemic control by the novel mechanism of skeletal muscle microvascular recruitment.
Verrier RL
J Physiol; 2013 Oct; 591(20):4961. PubMed ID: 24130322
[No Abstract] [Full Text] [Related]
2. Ranolazine recruits muscle microvasculature and enhances insulin action in rats.
Fu Z; Zhao L; Chai W; Dong Z; Cao W; Liu Z
J Physiol; 2013 Oct; 591(20):5235-49. PubMed ID: 23798495
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiologic basis for the antiarrhythmic actions of ranolazine.
Antzelevitch C; Burashnikov A; Sicouri S; Belardinelli L
Heart Rhythm; 2011 Aug; 8(8):1281-90. PubMed ID: 21421082
[TBL] [Abstract][Full Text] [Related]
4. The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit.
Hale SL; Kloner RA
J Cardiovasc Pharmacol Ther; 2008 Sep; 13(3):226-32. PubMed ID: 18625805
[TBL] [Abstract][Full Text] [Related]
5. Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons.
Peters CH; Sokolov S; Rajamani S; Ruben PC
Br J Pharmacol; 2013 Jun; 169(3):704-16. PubMed ID: 23472826
[TBL] [Abstract][Full Text] [Related]
6. Antifibrillatory effect of ranolazine during severe coronary stenosis in the intact porcine model.
Nieminen T; Nanbu DY; Datti IP; Vaz GR; Tavares CA; Pegler JR; Nearing BD; Belardinelli L; Verrier RL
Heart Rhythm; 2011 Apr; 8(4):608-14. PubMed ID: 21094698
[TBL] [Abstract][Full Text] [Related]
7. Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability.
Estacion M; Waxman SG; Dib-Hajj SD
Mol Pain; 2010 Jun; 6():35. PubMed ID: 20529343
[TBL] [Abstract][Full Text] [Related]
8. Ranolazine attenuates hypoxia- and hydrogen peroxide-induced increases in sodium channel late openings in ventricular myocytes.
Ma J; Song Y; Shryock JC; Hu L; Wang W; Yan X; Zhang P; Belardinelli L
J Cardiovasc Pharmacol; 2014 Jul; 64(1):60-8. PubMed ID: 24705174
[TBL] [Abstract][Full Text] [Related]
9. Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart.
Carvas M; Nascimento BC; Acar M; Nearing BD; Belardinelli L; Verrier RL
J Cardiovasc Pharmacol; 2010 Mar; 55(3):286-91. PubMed ID: 20075744
[TBL] [Abstract][Full Text] [Related]
10. Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle.
McCormack JG; Baracos VE; Barr R; Lopaschuk GD
J Appl Physiol (1985); 1996 Aug; 81(2):905-10. PubMed ID: 8872662
[TBL] [Abstract][Full Text] [Related]
11. Globular adiponectin enhances muscle insulin action via microvascular recruitment and increased insulin delivery.
Zhao L; Chai W; Fu Z; Dong Z; Aylor KW; Barrett EJ; Cao W; Liu Z
Circ Res; 2013 Apr; 112(9):1263-71. PubMed ID: 23459195
[TBL] [Abstract][Full Text] [Related]
12. Electrocardiological effects of ranolazine and lidocaine on normal and diabetic rat atrium.
Khazraei H; Mirkhani H; Shabbir W
J Interv Card Electrophysiol; 2021 Apr; 60(3):387-394. PubMed ID: 32328860
[TBL] [Abstract][Full Text] [Related]
13. Ranolazine, a novel agent for chronic stable angina.
Gaffney SM
Pharmacotherapy; 2006 Jan; 26(1):135-42. PubMed ID: 16506355
[TBL] [Abstract][Full Text] [Related]
14. Ranolazine: Déjà vu of the amiodarone story.
Viskin S; Adler A
Heart Rhythm; 2011 Aug; 8(8):1291-2. PubMed ID: 21699867
[No Abstract] [Full Text] [Related]
15. The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than in nondiabetic rats.
Mourouzis I; Mantzouratou P; Galanopoulos G; Kostakou E; Dhalla AK; Belardinelli L; Pantos C
J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):457-69. PubMed ID: 24651516
[TBL] [Abstract][Full Text] [Related]
16. Ranolazine block of human Na v 1.4 sodium channels and paramyotonia congenita mutants.
El-Bizri N; Kahlig KM; Shyrock JC; George AL; Belardinelli L; Rajamani S
Channels (Austin); 2011; 5(2):161-72. PubMed ID: 21317558
[TBL] [Abstract][Full Text] [Related]
17. The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease.
Stone PH; Chaitman BR; Stocke K; Sano J; DeVault A; Koch GG
J Am Coll Cardiol; 2010 Sep; 56(12):934-42. PubMed ID: 20828645
[TBL] [Abstract][Full Text] [Related]
18. Cardiac sodium channel Na(v)1.5 mechanosensitivity is inhibited by ranolazine.
Abriel H
Circulation; 2012 Jun; 125(22):2681-3. PubMed ID: 22565937
[No Abstract] [Full Text] [Related]
19. Insulin-induced changes in skeletal muscle microvascular perfusion are dependent upon perivascular adipose tissue in women.
Meijer RI; Serné EH; Korkmaz HI; van der Peet DL; de Boer MP; Niessen HW; van Hinsbergh VW; Yudkin JS; Smulders YM; Eringa EC
Diabetologia; 2015 Aug; 58(8):1907-15. PubMed ID: 26003324
[TBL] [Abstract][Full Text] [Related]
20. Ranolazine for atrial fibrillation: buy one get three beneficial mechanisms!
Maier LS
Eur J Heart Fail; 2012 Dec; 14(12):1313-5. PubMed ID: 23112001
[No Abstract] [Full Text] [Related]
[Next] [New Search]
